Barclays Maintains Overweight on 10x Genomics, Raises Price Target to $110
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsPrice Target
Barclays analyst Luke Sergott maintains 10x Genomics (NASDAQ:TXG) with a Overweight and raises the price target from $52 to $110.
Barclays analyst Luke Sergott maintains 10x Genomics (NASDAQ:TXG) with a Overweight and raises the price target from $52 to $110.